Floatz logo

FLUORTHANATRACE F-18

Prostate Cancer Metastatic

Abramson Cancer Center at Penn MedicineSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

251 Active assets in the Prostate Cancer Metastatic cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

FLUORTHANATRACE F-18 is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
neuroendocrine carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →